Vol 17, No 2 (2020)
Prace poglądowe - nadesłane
Get Citation

Aripiprazole at maximum dose and in combination with olanzapine

Paweł Mierzejewski
DOI: 10.5603/PSYCH.2020.0013
·
Psychiatria 2020;17(2):71-75.

paid access

Vol 17, No 2 (2020)
Prace poglądowe - nadesłane

Abstract

Aripiprazole is an antipsychotic drug with unique pharmacological properties showing ago-antagonistic effects against the D2 receptor and is classified as a III generation antipsychotic. Clinical and preclinical studies indicate efficacy and safety of high doses of aripiprazole in selected patients, supporting the decision to use the drug at a maximum dose of 30 mg/day. This paper presents the mechanism of action of high doses of aripiprazole and discusses clinical situations when it is appropriate to use the drug at the maximum dose. The second part of the study presents arguments for beneficial effects of the combination of aripiprazole with olanzapine and other antipsychotic drugs of II generation.

Abstract

Aripiprazole is an antipsychotic drug with unique pharmacological properties showing ago-antagonistic effects against the D2 receptor and is classified as a III generation antipsychotic. Clinical and preclinical studies indicate efficacy and safety of high doses of aripiprazole in selected patients, supporting the decision to use the drug at a maximum dose of 30 mg/day. This paper presents the mechanism of action of high doses of aripiprazole and discusses clinical situations when it is appropriate to use the drug at the maximum dose. The second part of the study presents arguments for beneficial effects of the combination of aripiprazole with olanzapine and other antipsychotic drugs of II generation.

Get Citation
About this article
Title

Aripiprazole at maximum dose and in combination with olanzapine

Journal

Psychiatria (Psychiatry)

Issue

Vol 17, No 2 (2020)

Pages

71-75

DOI

10.5603/PSYCH.2020.0013

Bibliographic record

Psychiatria 2020;17(2):71-75.

Authors

Paweł Mierzejewski

References (20)
  1. Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des. 2010; 16(5): 488–501.
  2. Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs. 2004; 18(4): 251–267.
  3. Nagai T, Murai R, Matsui K, et al. Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology (Berl). 2009; 202(1-3): 315–328.
  4. Di Sciascio G, Riva MA. Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatr Dis Treat. 2015; 11: 2635–2647.
  5. Ribeiro EL, de Mendonça Lima T, Vieira ME, et al. Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews. Eur J Clin Pharmacol. 2018; 74(10): 1215–1233.
  6. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013; 382(9896): 951–962.
  7. Sparshatt A, Taylor D, Patel MX, et al. A systematic review of aripiprazole--dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry. 2010; 71(11): 1447–1456.
  8. Keck PE, Marcus R, Tourkodimitris S, et al. Aripiprazole Study Group. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003; 160(9): 1651–1658.
  9. Gerner RH, Post RM, Bunney WE. A dopaminergic mechanism in mania. Am J Psychiatry. 1976; 133(10): 1177–1180.
  10. Mamo D, Graff A, Mizrahi R, et al. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry. 2007; 164(9): 1411–1417.
  11. Natesan S, Reckless GE, Nobrega JN, et al. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology. 2006; 31(9): 1854–1863.
  12. Citrome L, Macher JP, Salazar DE, et al. Pharmacokinetics of aripiprazole and concomitant carbamazepine. J Clin Psychopharmacol. 2007; 27(3): 279–283.
  13. Belmonte C, Ochoa D, Román M, et al. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers. Basic Clin Pharmacol Toxicol. 2018; 122(6): 596–605.
  14. Findling RL, Robb A, Nyilas M, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008; 165(11): 1432–1441.
  15. Byerly MJ, Marcus RN, Tran QV, et al. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr Res. 2009; 107(2-3): 218–222.
  16. Newcomer JW, Campos JA, Marcus RN, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry. 2008; 69(7): 1046–1056.
  17. Englisch S, Zink M. Combined antipsychotic treatment involving clozapine and aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(6): 1386–1392.
  18. Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999; 37(3): 177–193.
  19. Duggal HS. Aripirazole-olanzapine combination for treatment of schizophrenia. Can J Psychiatry. 2004; 49(2): 151.
  20. Choi YJ. Efficacy of adjunctive treatments added to olanzapine or clozapine for weight control in patients with schizophrenia: a systematic review and meta-analysis. ScientificWorldJournal. 2015; 2015: 970730.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Psychiatria dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl